Background
Methods
Results
Baseline characteristic | Lithium (n = 23) | Placebo (n = 30) | p value |
---|---|---|---|
Gender | |||
Male | n = 1 (4%) | n = 4 (13%) | 0.374e
|
Female | n = 22 (96%) | n = 26 (87%) | |
Age | 37.7 ± 8.1a years | 40.8 ± 8.54a years | 0.186c
|
Weight | 68.5 ± 16.2a kg | 71.2 ± 12.7a kg | 0.493c
|
Months on ART | 33 (12–56)b months | 40 (26–68)b months | 0.262d
|
Renal function | |||
Creatinine | 58 (49–62)b µmol/L | 58.5 (50–68)b µmol/L | 0.404d
|
eGFR MDRD | 139.3 (118.1–159.7)b mL/min | 131.0 (110.9–156.9)b mL/min | 0.572d
|
eGFR MDRD changed
| Treatment arm | Week 4 % (n) | Week 8 % (n) | Week 12 % (n) | Week 16 % (n) | Week 20 % (n) | Week 24 % (n) |
---|---|---|---|---|---|---|---|
Increased | Lithium | 30.4% (7/23) | 39.1% (9/23) | 39.1% (9/23) | 34.8% (8/23) | 39.1% (9/23) | 56.5% (13/23) |
Placebo | 40% (12/30) | 50% (15/30) | 43.3% (13/30) | 33.3% (10/30) | 43.3% (13/30) | 46.7% (14/30) | |
p = 0.518a
| p = 0.621a
| p = 0.095a
| p = 0.012a
| p = 0.095a
| p = 0.506a
| ||
Grade 1 Decreased 0.1% to <10% from baseline | Lithium | 34.8% (8/23) | 13% (3/23) | 8.7% (2/23) | 26.1% (6/23) | 17.4% (4/23) | 8.7% (2/23) |
Placebo | 23.3% (7/30) | 16.7% (5/30) | 20% (6/30) | 23.3% (7/30) | 30% (9/30) | 20% (6/30) | |
p = 0.495a
| p = 0.264b
| p = 0.229b
| p = 0.817a
| p = 0.233b
| p = 0.229b
| ||
Grade 2 Decreased 10 to <30% from baseline | Lithium | 26.0% (6/23) | 26.1% (9/23) | 43.5% (10/23) | 21.7% (5/23) | 34.8% (8/23) | 23% (6/23) |
Placebo | 26.7% (8/30) | 13.3% (5/30) | 30% (9/30) | 33.3% (10/30) | 13.3% (4/30) | 30% (9/30) | |
p = 0.971a
| p = 0.164a
| p = 0.765a
| p = 0.484a
| p = 0.145a
| p = 0.814b
| ||
Grade 3 Decreased ≥30 to <50% from baseline | Lithium | 8.7% (2/23) | 8.7% (2/23) | 8.7% (2/23) | 8.7% (2/23) | 8.7% (2/23) | 8.7% (2/23) |
Placebo | 0% | 0% | 3.3% (1/30) | 0% | 13.3% (4/30) | 3.3% (1/30) | |
p = 0.202b
| p = 0.202b
| p = 0.418b
| p = 0.202b
| p = 0.493b
| p = 0.418b
| ||
Grade 4 Decreased ≥50% from baseline | Lithium | 0% | 0% | 0% | 0% | 0% | 0% |
Placebo | 0% | 0% | 0% | 3.3% (1/30) | 0% | 0% | |
p = 574b
| |||||||
Creatinine not measuredc
| Lithium | 0% | 0% | 0% | 4.3% (1/23) | 0% | 0% |
Placebo | 0% | 10% (3/30) | 3.3% (1/30) | 3.3% (1/30) | 0% | 0% | |
p = 0.197b
| p = 0.574b
| p = 0.687b
|